Loading
A phase 1/2 trial of SHR-8068 in renal cell carcinoma, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.
Phase Ib/II Clinical Study of SHR-8068 Combined Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom is a phase 1/2 interventional study registered as NCT07239596 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 92 participants planned, started 2026-01-06 and due to reach its primary completion in 2030-12. Interventions recorded: SHR-8068；Adebrelimab ；Bevacizumab, SHR-8068 ; SHR-4610. Conditions listed: Advanced Renal Cell Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares SHR-8068, Jiangsu Hengrui Pharmaceuticals.
Shares SHR-8068, Jiangsu Hengrui Pharmaceuticals.
Shares SHR-8068, Jiangsu Hengrui Pharmaceuticals.
Shares SHR-8068, Jiangsu Hengrui Pharmaceuticals.
Shares SHR-8068, Jiangsu Hengrui Pharmaceuticals.
Shares SHR-8068, Jiangsu Hengrui Pharmaceuticals.
Shares SHR-8068, Jiangsu Hengrui Pharmaceuticals.
Shares SHR-8068, Jiangsu Hengrui Pharmaceuticals.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/